Severe Imipramine-Induced Myoclonus in a Patient with Psychotic Bipolar Depression, Catatonia, and Schizencephaly

REFERENCES

• Lejoyeux M, Rouillon F, Ades J, Gorwood P: Neural symp-toms induced by tricyclic antidepressants: phenomenology and pathophysiology. Ada Psychiatr Scand 1992; 85:249–256
   Google Scholar
• Riley DE: Antidepressant therapy and movement disorders. In: Lang AE, Weiner WJ, eds. Drug-Induced Movement Dis-orders. Mount Kisco, NY: Futura Publishing Co; 1992:231–255
   Google Scholar
• Burks JS, Walker JE, Rumack BH, Ott JE: Tricyclic antide-pressant poisoning: Reversal of coma, choreoathetosis, and myoclonus by physostigmine. JAMA 1974; 230:1405–1407
   PubMed Web of Science ®Google Scholar
• Noble J, Matthew H: Acute poisoning by tricyclic antidepres-sants: Clinical features and management of 100 patients. Clin Toxicol 1969; 2:403–407
   Web of Science ®Google Scholar
• Garvey Mi, Tollefson GD: Occurrence of myoclonus in pa-tients treated with cyclic antidepressants. Arch Gen Psychia-try 1987; 44:269–272
   PubMed Web of Science ®Google Scholar
• Patterson JF: Myoclonus caused by a tricyclic antidepressant. Southern Med J 1990; 83:463–465
   Google Scholar
• Darcourt 0, Gadeuilhe A, Lavagna J, Cazac A: Trois cas de myoclonies d'action au cours de traitements par Plmipramine et l'Amitriptyline. Rev Neurol 1970; 122:141–142
   Google Scholar
• Schulze B: Zur Frage medikamentos induzierter cerebraler Reaktionen: Ein Fall von myoklonischem Status tinter Be-handlung mit tricyclischen Antidepressiva. Nerventirit 1972; 43:332–336
   Google Scholar
• Lippmann S, Moskovitz R, O'Tuama L: Tricyclic-induced myoclonus. Am J Psychiatry 1977; 134:90–91
   Google Scholar
• Lippmann S, Tucker D, Wagemaker H, Schulte T: A second report of tricyclic-induced myoclonus. Am J Psychiatry 1977; 134:585–586
   Google Scholar
• DeCastro RM. Antidepressants and myoclonus: Case report. J Clin Psychiatry 1985; 46:284–287
   Google Scholar
• Kettl P, DePaulo Jr JR: Maprotiline-induced myoclonus. J Clin Psychopharmacol 1983; 3:264–265
   Google Scholar
• Fukuzako H, Hokazono Y, Tominaga H, Hirakawa K. Mat-sumoto K: Jerk-locked averaging and somatosensory evoked potential in tricyclic-induced myoclonus: A case report. Japan J Psychiatry Neurol 1989; 43:645–649
   Google Scholar
• Koller WC, Musa MN: Amitriptyline-induced abnormal movements. Neurology 1985; 35:1086
   Google Scholar
• Fahn S, Marsden CD, Van Woert MH: Definition and clas-sification of myoclonus. Adv Neurol 1986; 43:1–5
   PubMedGoogle Scholar
• Casas M, Garcia-Ribera C, Alvarez E, Udina C, Ma Queralto J, Ma Grau J: Myoclonic movements as a side-effect of treat-ment with therapeutic doses of clomipramine. Int Clin Psy-chopharmacol 1987; 2:333–336
   Google Scholar
• Cohen RM, Pickar D, Murphy DL: Myoclonus-associated hy-pomania during MAO-inhibitor treatment. Am J Psychiatry 1980; 137:105–106
   PubMedGoogle Scholar
• Lohr JB, Wisniewski AA: Movement Disorders: A Neuro-psychiatric Approach. New York: Guilford Press; 1987
   Google Scholar
• Salam SA, Kilzieh N: Lorazepam treatment of psychogenic catatonia: an update. J Clin Psychiatry 1988; 49(suppI):16–21
   Google Scholar
• Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF: Catatonic syndrome in a general psychiatric inpatient popu-lation: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357–362
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Mandel MR: Catatonic reactions to high-po-tency neuroleptic drugs. Arch Gen Psychiatry 1977; 34:947–950
   PubMed Web of Science ®Google Scholar
• Abrams R, Taylor MA: Catatonia: a prospective clinical study. Arch Gen Psychiatry 1976; 33:579–581
   PubMed Web of Science ®Google Scholar
• Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA: The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 1986; 49:991–996
   PubMed Web of Science ®Google Scholar
• Barkovich AJ, Kjos BO: Schizencephaly: correlation of clini-cal findings with MR characteristics. Am J Neuroradiol 1992; 13:85–94
   PubMed Web of Science ®Google Scholar
• Miller GM, Stears JC, Guggenheim MA, Wilkening GN: Schizeneephaly: a clinical and CT study. Neurology 1984; 34:997–1001
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Kane JM, Reife R: Neuromuscular effects of monoamine oxidase inhibitors. Adv Neurol 1986; 43:231–249
   Google Scholar
• Askenasy JJ, Yahr MD: Is monoamine oxidase inhibitor in-duced myoclonus serotoninergically mediated? J Neural Transm 1988; 72:67–76
   Google Scholar
• Klawans HL, Carvey PM, Tanner CM, Goetz CG: Drug-in-duced myoclonus. Adv Neurol 1986; 43:251–264
   PubMedGoogle Scholar
• Aniskiewicz AS, Frumkin NL, Brady DE, Moore JB, Pera A: Magnetic resonance imaging and neurobehavioral correlates in schizeneephaly. Arch Neurol 1990; 47:911–916
   PubMedGoogle Scholar